Mindray Expands Its Cardiac Biomarker Portfolio with Cutting-Edge hs-cTnI and NT-proBNP Assays, Empowering Enhanced Cardiovascular Diseases Care
The additions have enhanced Mindray's diverse portfolio of cardiac biomarkers for cardiovascular diseases (CVDs) diagnosis and management.
- The additions have enhanced Mindray's diverse portfolio of cardiac biomarkers for cardiovascular diseases (CVDs) diagnosis and management.
- While CVDs are the leading cause of death worldwide, early detection is key in saving lives.
- The two assays are the collaborative effort of Mindray and HyTest, a Mindray company and a prominent global provider of antibodies and antigens.
- HyTest, renowned for its cardiac biomarker expertise, had its cardiac troponin complex material selected as the international troponin standard by AACC in 2004.